⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8012774 | 0.87 | — | — | |
| SCHEMBL7823874 | 0.86 | — | — | |
| SCHEMBL20693673 | 0.85 | — | — | |
| SCHEMBL7846557 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL8016902 | 0.85 | — | — | |
| Water SCHEMBL8106676 | 0.84 | — | — | |
| Water SCHEMBL8099309 | 0.84 | — | — | |
| SCHEMBL8474250 | 0.83 | — | — | |
| SCHEMBL7836125 | 0.82 | — | — | |
| SCHEMBL7820517 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | claimed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | claimed |
| EP-0820455-B1 | 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2001-10-31 | — | — | EP | claimed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-20130281541-A1 | USE IN BRAIN DEGENERATIVE DISEASES | BRINKMANN VOLKER (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8519006-B2 | Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-1871749-B1 | Selurampanel | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2005094797-A2 | USE OF AMPA-RECEPTOR ANTAGONISTS FOR TREATING DEMENTIA | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005058295-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005049039-A1 | COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049042-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TINNITUS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049041-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049040-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005039594-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MYOPIA | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039593-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-6057454-A | USEFUL FOR TREATING OR PREVENTING ALL ISCHAEMIAS (SUCH AS FOCAL OR GLOBAL ISCHAEMIA) RESULTING FROM CEREBROVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2000-05-02 | — | — | US | disclosed |